Acral peeling skin syndrome is a rare inherited condition in which the outermost layer of skin on the hands and feet sheds spontaneously and painlessly, often in visible sheets or flaps. It belongs to a broader family of peeling skin disorders but is distinguished by its restriction to the “acral” areas, meaning the palms, soles, and backs of the hands and feet. The condition is lifelong, has no cure, and is caused by genetic mutations that weaken the glue holding together the outermost skin cells. Despite its dramatic appearance, the peeling itself is typically painless, which is part of why it can go unrecognized or misdiagnosed for years.
How the Skin Comes Apart
Healthy skin depends on protein cross-links that bond the outermost dead cell layer (the stratum corneum) to the living layers beneath it. In acral peeling skin syndrome, those cross-links are defective. The enzyme transglutaminase 5, which normally stitches together structural proteins in the outer epidermis, either works poorly or not at all. Without that scaffolding, the bond between the granular layer and the stratum corneum fails, and sheets of dead skin lift away from the surface.1PubMed Central. A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome
Microscopy of affected skin confirms where the split happens. Biopsy specimens show a cleft forming within the stratum corneum itself, along with abnormal keratohyalin granules and poor aggregation of the protein filaments that normally reinforce the outer skin. When the skin is soaked in water, separation becomes even more obvious under the microscope, which matches patients’ common experience that moisture makes peeling worse.2PubMed. Acral peeling skin syndrome
The result is painless but visually striking. Skin peels in translucent or whitish sheets, sometimes leaving a reddened surface underneath that heals on its own without scarring. Because the separation occurs in the dead-cell layer rather than deeper down, there is usually no bleeding, blistering in the traditional sense, or infection risk from the peeling itself. That said, some individuals do develop more prominent blisters, which can complicate the picture and cause real discomfort.
The Genetic Roots
Acral peeling skin syndrome follows an autosomal recessive inheritance pattern, meaning a person needs to inherit a faulty copy of the relevant gene from each parent to develop the condition. Carriers who have only one faulty copy generally show no symptoms.
The first gene identified behind APSS was TGM5, which encodes transglutaminase 5. Researchers studying two unrelated families found homozygous missense mutations in TGM5 in all six affected family members. One of those mutations, called G113C, was shown in laboratory assays to completely abolish the enzyme’s cross-linking activity, directly explaining why the skin falls apart.3PubMed Central. A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome Additional TGM5 mutations have been documented since, reinforcing the gene’s central role in maintaining structural integrity of the outermost skin layers.4PubMed. Novel TGM5 mutations in acral peeling skin syndrome
TGM5 is not the whole story, though. APSS is genetically heterogeneous, a term that simply means that more than one gene can cause the same clinical picture. A second gene, CSTA, which encodes a protein called cystatin A, has been linked to both APSS and a related condition called exfoliative ichthyosis.5American Journal of Human Genetics. Loss-of-Function Mutations in CAST Cause Peeling Skin, Leukonychia, Acral Punctate Keratoses, Cheilitis, and Knuckle Pads In some families, large deletions encompassing part of the CSTA gene have been confirmed as the cause, even when TGM5 is completely normal.6Clinical and Experimental Dermatology. Acral peeling skin syndrome associated with a novel CSTA gene mutation
And even those two genes don’t account for everyone. A large Jordanian family with at least ten affected members was studied, and sequencing of TGM5 turned up no pathogenic mutations at all. Genome-wide mapping found areas of interest on several chromosomes, but none contained genes with an obvious connection to skin barrier function.7PubMed. Acral peeling skin syndrome: a clinically and genetically heterogeneous disorder This means there are still undiscovered genes involved, which is one reason genetic testing sometimes comes back inconclusive for families seeking a definitive diagnosis.
What Triggers Flare-Ups
Although the underlying defect is present at all times, the severity of peeling fluctuates. The most commonly reported triggers are heat, humidity, and friction.8Journal of Dermatological Science. Homozygous TGM5 mutation in a European family with acral peeling skin syndrome In warmer months or tropical climates, patients often experience much worse peeling than during cooler, drier seasons. Physical activity, prolonged wearing of occlusive gloves or shoes, and contact with water can all accelerate the separation process.
This trigger profile creates a frustrating pattern for people with the condition. Activities that involve hand use, sweating, or moisture exposure become reliably associated with peeling episodes. Tasks like cooking, manual work, exercise, or simply walking in warm weather can leave the skin on the hands and feet in shreds within hours. Some patients report that even the friction of holding a pen or gripping a steering wheel is enough to start a peel on a bad day.
Importantly, these triggers do not cause the condition. They expose the underlying weakness. A person with healthy transglutaminase 5 activity can sweat through a summer day with no skin peeling. In someone with APSS, that same sweat and heat simply accelerates the failure of an already fragile bond.
How Acral Peeling Skin Syndrome Gets Diagnosed
Because APSS is rare and the peeling can look superficially like contact dermatitis, eczema, or even a fungal infection, many patients cycle through multiple incorrect diagnoses before landing on the right one. The typical path to diagnosis involves three elements: clinical presentation, biopsy, and genetic testing.
Clinically, the key distinguishing feature is that the peeling is painless, non-inflammatory, and confined to the hands and feet. There is no history of exposure to a specific irritant, which helps rule out contact dermatitis. Biopsy of a peeling area reveals the characteristic intracorneal cleft, meaning the split happens within the stratum corneum rather than at a deeper layer, along with subtle changes like reduced granular-layer thickness and focal areas where the normal maturation pattern of skin cells is disrupted.9Central European Journal of Paediatrics. Acral Peeling Skin Syndrome: A Rare Skin Disorder
Genetic testing can confirm the diagnosis by identifying mutations in TGM5 or CSTA. In one reported case, two pathogenic variants in TGM5 were found in a compound heterozygous pattern, meaning the patient inherited a different mutation from each parent rather than two copies of the same one.10Central European Journal of Paediatrics. Acral Peeling Skin Syndrome: A Rare Skin Disorder When genetic testing is negative for known genes, the diagnosis can still be made on clinical and histological grounds, but families may be left without a precise genetic explanation.
Conditions That Look Similar but Aren’t
Several other skin disorders can produce peeling on the hands and feet, and distinguishing APSS from them matters for management and prognosis. A South African case report laid out the differential diagnosis clearly:
- Contact dermatitis: Peeling follows exposure to a specific irritant or allergen and typically comes with redness, itching, or burning. APSS peeling is spontaneous and painless.
- Keratolytic winter erythema: Also called Oudtshoorn disease, this autosomal dominant disorder causes peeling of the palms and soles primarily in winter. It is almost exclusively found in the Afrikaner population of South Africa’s Western Cape.
- Netherton syndrome: An autosomal recessive disorder that usually presents in early childhood with widespread skin redness, scaling, allergic features like high IgE levels, and a distinctive “bamboo hair” abnormality. It carries a risk of fatal complications in early childhood that APSS does not.
- Epidermolysis bullosa simplex: An autosomal dominant blistering disorder caused by mutations in different genes entirely. Unlike APSS, it produces true fluid-filled blisters rather than dry, painless skin separation.
Each of these conditions has a distinct genetic basis, inheritance pattern, and set of associated features that a dermatologist can use to tell them apart.11PubMed Central. Adult-Onset Acral Peeling Skin Syndrome in a Non-Identical Twin: A Case Report in South Africa A family history of similar symptoms strongly points toward a recessive condition like APSS, especially if both parents are unaffected.
Generalized Peeling Skin Syndrome and Where APSS Fits
APSS is one branch of a broader category called peeling skin syndrome. The term was first introduced in 1982 by Levy and Goldsmith, though a similar condition had been described as far back as 1921 under a different name. The classification recognizes two main clinical variants: a generalized form, in which peeling can affect the entire body, and the acral form, in which peeling is restricted to the hands and feet.12PubMed Central. Adult-Onset Acral Peeling Skin Syndrome in a Non-Identical Twin: A Case Report in South Africa
The generalized form tends to be more severe and may involve additional features like redness, itching, or short stature. It is associated with mutations in CDSN, a gene encoding a protein that holds skin cells together in a slightly different way than transglutaminase 5. In contrast, acral peeling skin syndrome is typically milder, limited in distribution, and associated with TGM5 or CSTA mutations. Both variants are autosomal recessive. The distinction matters because the generalized form can affect overall health more broadly, while APSS is primarily a cosmetic and quality-of-life concern.
Treatment Options and Their Limits
There is no treatment that addresses the underlying genetic defect in APSS. Management has been and remains symptomatic, and the track record of conventional therapies is not encouraging. Emollients, antihistamines, keratolytic agents, corticosteroids, methotrexate, isotretinoin, and even ultraviolet light therapy have all been tried, generally with limited success.13American Journal of Case Reports. Adult-Onset Acral Peeling Skin Syndrome in a Non-Identical Twin: A Case Report in South Africa
The logic behind emollients is straightforward: keeping the skin hydrated might slow or reduce peeling. In practice, heavy moisturizers and barrier creams can provide modest improvement for some patients, but they do not prevent the underlying separation from occurring. Keratolytics, which work by softening and dissolving the outer skin layer, might seem counterintuitive for a peeling disorder, but the idea is to manage the peeling in a controlled way rather than letting ragged sheets of skin catch and tear. Results vary.
The most interesting recent development involves botulinum toxin, best known by its cosmetic brand names. Two related patients with APSS, a 27-year-old woman and her 24-year-old male cousin, both experienced marked worsening of their peeling with warm weather, physical activity, and occlusion. After conventional topical treatments failed to control their symptoms, both received intradermal injections of botulinum toxin A into the palms and soles. The results were striking: blistering and peeling dropped substantially, and both patients reported meaningful improvement in their daily lives.14PubMed Central. Acral Peeling Skin Syndrome: Two Unusual Cases and the Therapeutic Potential of Botulinum Toxin
The probable mechanism is that botulinum toxin reduces sweating. Since moisture is a major trigger for peeling, blocking the sweat glands in the palms and soles cuts off one of the key aggravating factors. This does not fix the genetic defect, but it removes the environmental provocation. Two cases are far from proof that this works universally, and botulinum toxin injections into the palms and soles are quite painful without nerve blocks. Still, for patients whose lives are substantially impaired and who have exhausted other options, the approach represents a genuinely new direction.
Living with APSS Day to Day
Because the condition has no effective cure, people with APSS develop their own strategies for managing it. Avoidance of known triggers is the most practical lever. Keeping hands and feet cool and dry, choosing breathable footwear, avoiding prolonged glove use, and reducing friction where possible can all reduce the frequency and severity of peeling episodes. Some patients find that applying emollients at night under cotton gloves or socks allows the moisturizer to work without trapping too much heat.
The cosmetic impact deserves mention. Visible peeling on the hands is socially noticeable, and people with APSS report that others sometimes assume their condition is contagious or related to poor hygiene. Neither is true. The disorder cannot be transmitted, and it has nothing to do with handwashing habits or skin care routines. Educating friends, coworkers, and teachers (in the case of children) can reduce the social burden, but the reality is that visible skin conditions carry stigma regardless of how much education takes place.
Occupational considerations come into play as well. Jobs that require frequent handwashing, glove use, manual labor, or work in hot environments are likely to worsen symptoms. People with APSS who can choose or modify their work environment to minimize these exposures tend to have an easier time managing the condition. For school-age children, gym class and outdoor activities in summer may need accommodations.
Why APSS Research Moves Slowly
Rare diseases in general face a research-funding problem, and APSS is no exception. The condition is uncommon enough that large clinical trials are essentially impossible. Most of what is known comes from case reports involving single families or small series of patients. A review of peeling skin diseases in Turkey examined 21 cases across the entire spectrum of peeling disorders, which gives a sense of how infrequently these conditions appear even in a large dermatology practice.15PubMed. Peeling skin diseases: 21 cases from Turkey and a review of the literature
The genetic heterogeneity described earlier adds another layer of difficulty. Because not all cases of APSS trace to the same gene, a treatment developed around TGM5 function might not help someone whose condition stems from a CSTA mutation or from a gene that hasn’t been identified yet. Each genetic subtype could, in theory, require its own therapeutic approach. For conditions this rare, that level of specificity is a tall order.
Gene therapy, which has begun showing results in other inherited skin disorders like some forms of epidermolysis bullosa, is a theoretical possibility for APSS. But the path from concept to clinical use is long, expensive, and generally pursued only when commercial or philanthropic incentives exist. For the foreseeable future, people with APSS are likely to rely on trigger avoidance, emollients, and potentially approaches like botulinum toxin that address downstream symptoms rather than the genetic root.
When Peeling Starts Later in Life
Most cases of APSS are recognized in childhood, which makes sense for a genetic condition present from birth. However, a noteworthy case from South Africa described adult-onset acral peeling skin syndrome in a woman who was a non-identical twin, with her twin sister unaffected.16PubMed Central. Adult-Onset Acral Peeling Skin Syndrome in a Non-Identical Twin: A Case Report in South Africa The late onset raises questions. One possibility is that the condition was present at a mild, unnoticed level earlier in life and was only recognized once environmental triggers (occupation, climate, lifestyle) pushed symptoms past a threshold. Another is that modifier genes or epigenetic factors can influence when and how severely the condition manifests.
This matters for adults who develop unexplained peeling on the hands and feet. It is easy to assume that any new skin peeling in adulthood must be acquired rather than genetic, and dermatologists may not think to consider APSS in an adult patient. The South African case is a reminder that the condition should be on the differential list regardless of the patient’s age, particularly when the peeling is painless, non-inflammatory, and unresponsive to standard treatments for eczema or dermatitis. Genetic testing is available and can provide a definitive answer even decades after symptoms begin.